Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer
- 16 April 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 62 (5), 909-918
- https://doi.org/10.1007/s00262-013-1396-8
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survivalNature Medicine, 2012
- Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung CancerClinical Cancer Research, 2006
- Randomized Phase II Trials: What Does Randomization Gain?Journal of Clinical Oncology, 2005
- Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2005
- Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiencyBreast Cancer Research, 2005
- All‐trans retinoic acid skews monocyte differentiationinto interleukin‐12‐secreting dendritic‐like cellsBritish Journal of Haematology, 2003
- All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.2003
- Treatment of relapsed small-cell lung cancer—a focus on the evolving role of topotecanLung Cancer, 2003
- Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients.2001
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989